Cytokinetics (CYTK) January calls and puts active
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Wall Street bullish on Cytokinetics (CYTK) following positive trial results
December 28, 2023 7:55 AM ESTCytokinetics (NASDAQ: CYTK) shares surged more than 82% Wednesday on the back of the positive results from its experimental heart treatment study.
Cytokinetics revealed that in a key Phase 3 study, its drug, Aficamten, "significantly improved exercise capacity compared to placebo." Here's how Wall Street analysts reacted to the news:
Barclays analyst Carter Gould raised the firm's price target for CYTK to $100 per share... More
